Platelet-Rich Plasma Treatment for Ligament and Tendon Injuries
- 1 January 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of Sport Medicine
- Vol. 21 (1), 37-45
- https://doi.org/10.1097/jsm.0b013e31820758c7
Abstract
Platelet-rich plasma (PRP) is derived from centrifuging whole blood, has a platelet concentration higher than that of the whole blood, is the cellular component of plasma that settles after centrifugation, and contains numerous growth factors. There is increasing interest in the sports medicine and athletic community about providing endogenous growth factors directly to the injury site, using autologous blood products such as PRP, to potentially facilitate healing and earlier return to sport after musculoskeletal injury. Despite this interest, and apparent widespread use, there is a lack of high-level evidence regarding randomized clinical trials assessing the efficacy of PRP in treating ligament and tendon injuries. Basic science and animal studies and small case series reports on PRP injections for ligament or tendon injuries, but few randomized controlled clinical trials have assessed the efficacy of PRP injections and none have demonstrated scientific evidence of efficacy. Scientific studies should be performed to assess clinical indications, efficacy, and safety of PRP, and this will require appropriately powered randomized controlled trials with adequate and validated clinical and functional outcome measures and sound statistical analysis. Other aspects of PRP use that need to be determined are (1) volume of injection/application, (2) most effective preparation, (3) buffering/activation, (4) injection technique (1 depot vs multiple depots), (5) timing of injection to injury, (6) single application versus series of injections, and (7) the most effective rehabilitation protocol to use after PRP injection. With all proposed treatments, the doctor and the patient should weigh up potential benefits of treatment, potential risks, and costs. Based on the limited publications to date and theoretical considerations, the potential risks involved with PRP are fortunately very low. However, benefits remain unproven to date, particularly when comparing PRP with other injections for ligament and tendon injuries.Keywords
This publication has 43 references indexed in Scilit:
- Autologous growth factor injections in chronic tendinopathy: a systematic reviewBritish Medical Bulletin, 2010
- Platelet-rich plasma: any substance into it?British Journal of Sports Medicine, 2010
- Platelet-Rich PlasmaThe American Journal of Sports Medicine, 2009
- The biology of platelet-rich plasma and its application in trauma and orthopaedic surgeryThe Journal of Bone and Joint Surgery. British volume, 2009
- Enhanced histologic repair in a central wound in the anterior cruciate ligament with a collagen–platelet‐rich plasma scaffoldJournal of Orthopaedic Research, 2007
- Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound HealingPlastic and Reconstructive Surgery, 2004
- Types and epidemiology of tendinopathyClinics in Sports Medicine, 2003
- The Roles of Growth Factors in Tendon and Ligament HealingSports Medicine, 2003
- Platelet-Rich Plasma (PRP): What Is PRP and What Is Not PRP?Implant Dentistry, 2001
- Histopathology of Common TendinopathiesSports Medicine, 1999